“…How ever, the practical use of glycoprotein hormones in medicine is associated with a number of problems, including their lower resistance to proteolytic degra dation, high immunogenicity, the development of resistance of the target tissues to them, and the neces sity of parenteral administration. In view of this, the search for low molecular weight agonists of glycopro tein hormone receptors is carried out in recent years, which can penetrate the transmembrane channel, where the ligand binding site of most GPCRs is located, and cause the same structural changes in it that occur upon the binding of the glycoprotein hormone to the extracellular domain of the receptor [3,4].…”